Arch Therapeutics : Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.

FORM D Notice of Exempt Offering of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL OMB Number: 3235-0076 Expires: August 31, 2015 Estimated Average burden hours per response: 4.0

1. Issuer's Identity
CIK (Filer ID Number)	Previous Name(s)		None	Entity Type
0001537561	ALMAH, INC Almah, Inc. ALMAH,INC	Corporation Limited Partnership Limited Liability Company General Partnership Business Trust Other
Name of Issuer
Arch Therapeutics, Inc.
Jurisdiction of Incorporation/Organization
NEVADA
Year of Incorporation/Organization
Over Five Years Ago Within Last Five Years (Specify Year) Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Arch Therapeutics, Inc.

Street Address 1	Street Address 2
235 WALNUT STREET, SUITE 6

City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
FRAMINGHAM	MASSACHUSETTS	01702	617-431-2313

3. Related Persons

Last Name	First Name	Middle Name
Norchi	Terrence	W.

Street Address 1	Street Address 2
235 Walnut Street, Suite 6

City	State/Province/Country	ZIP/Postal Code
Framingham	MASSACHUSETTS	01702
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Dhillon	Punit

Street Address 1	Street Address 2
235 Walnut Street, Suite 6

City	State/Province/Country	ZIP/Postal Code
Framingham	MASSACHUSETTS	01702
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Sulat	James	R.

Street Address 1	Street Address 2
235 Walnut Street, Suite 6

City	State/Province/Country	ZIP/Postal Code
Framingham	MASSACHUSETTS	01702
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Davis	Richard	E.

Street Address 1	Street Address 2
235 Walnut Street, Suite 6

City	State/Province/Country	ZIP/Postal Code
Framingham	MASSACHUSETTS	01702
Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary)

4. Industry Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy

Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate

Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other

5. Issuer Size

Revenue Range	Aggregate Net Asset Value Range
	No Revenues		No Aggregate Net Asset Value
	$1 - $1,000,000		$1 - $5,000,000
	$1,000,001 - $5,000,000		$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000		$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000		$50,000,001 - $100,000,000
	Over $100,000,000		Over $100,000,000
	Decline to Disclose		Decline to Disclose
	Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
	Rule 504 (b)(1)(i)	Rule 506(b)
	Rule 504 (b)(1)(ii)	Rule 506(c)
	Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)

7. Type of Filing

New Notice

Date of First Sale

2021-02-11

First Sale Yet to Occur

Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

Yes

No

9. Type(s) of Securities Offered (select all that apply)

	Pooled Investment Fund Interests		Equity
	Tenant-in-Common Securities		Debt
	Mineral Property Securities		Option, Warrant or Other Right to Acquire Another Security
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?		Yes		No
Clarification of Response (if Necessary)

11. Minimum Investment

Minimum investment accepted from any outside investor	$	0	USD

12. Sales Compensation

Recipient Recipient CRD Number None H.C. Wainwright & Co. 375

(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number None

Street Address 1 Street Address 2 430 PARK AVENUE, 4TH FLOOR City State/Province/Country ZIP/Postal Code NEW YORK NEW YORK 10022

State(s) of Solicitation		All States		Foreign/Non-US

13. Offering and Sales Amounts

Total Offering Amount	$	7520000	USD		Indefinite
Total Amount Sold	$	6900000	USD
Total Remaining to be Sold	$	620000	USD		Indefinite

Clarification of Response (if Necessary)

14. Investors

	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	9

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$	492750	USD		Estimate
Finders' Fees	$	0	USD		Estimate

Clarification of Response (if Necessary)

Excludes value of warrants to purchase up to 3,234,375 shares at an exercise price of $0.20 per share

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$

0

USD

Estimate

Clarification of Response (if Necessary)

Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

	In submitting this notice, each Issuer named above is:
	Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees. Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed. Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date Arch Therapeutics, Inc. /s/ Terrrence Norchi Terrence Norchi President, Chief Executive Officer 2021-02-25